97 reports

This method avoids the gastrointestinal tract and leads to more rapid effects, compared to orally administered levodopa.

  • Dementia
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • EXELON

The patch formulation causes lesser gastrointestinal tract-related side effects (such as nausea and vomiting) than the Exelon capsule.

  • Dementia
  • Forecast
  • Allergan plc
  • Eisai Co., Ltd.
  • Novartis AG

Their research is focused on areas of expertise in neurology and gastrointestinal diseases, as Theyll as oncology.

  • Dementia
  • China
  • Guizhou Yibai Pharmaceutical Co., Ltd.
  • Novartis AG
  • Shandong Qilu Pharmaceutical Co., Ltd

TO THE BEGINNING OF THE ##ST CENTURY, SALES VOLUME OF SUCH DRUGS IS LIKELY TO EXCEED TOP THREE CARDIOVASCULAR DRUGS, GASTROINTESTINAL DRUGS AND ANTI-INFECTIVES.

  • Dementia
  • China
  • Demand
  • Market Size
  • Trade

TO THE BEGINNING OF THE ##ST CENTURY, SALES VOLUME OF SUCH DRUGS IS LIKELY TO EXCEED TOP THREE CARDIOVASCULAR DRUGS, GASTROINTESTINAL DRUGS AND ANTI-INFECTIVES.

  • Dementia
  • China
  • Trade
  • AstraZeneca China Inc.
  • Beijing Sihuan Pharmaceutical Co., Ltd.
  • 9.3 BIBLIOGRAPHY
  • 9 Appendix

The studies indicated in the heat map show that galantamine and rivastigmine both have higher incidences of Gastrointestinal (GI) side effects than donepezil.

  • Dementia
  • Asia
  • World
  • Forecast
  • Biogen Idec Inc.

Gastrointestinal and Respiratory drugs were the other major segments with ##% and ##% share respectively.

  • Dementia
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Their research is focused on areas of expertise in neurology and gastrointestinal diseases, as Theyll as oncology.

  • Dementia
  • China
  • Guizhou Yibai Pharmaceutical Co., Ltd.
  • Novartis AG
  • Shandong Qilu Pharmaceutical Co., Ltd
  • 10.1 All Pipeline Drugs by Phase

The studies indicated in the heat map show that galantamine and rivastigmine both have higher incidences of Gastrointestinal (GI) side effects than donepezil.

  • Dementia
  • World
  • Forecast
  • Market Size
  • Eisai Co., Ltd.

Gastrointestinal Tract HTT - Huntingtin - - - _ - - - - _ - - - - mRNA MRI ICD JPND MAOB MeSH MEW MHLW - - - - - - - - MSIF NA NCV NDA _ NMDA OMIM PEARLS PPMS PRMS RRMS sANDA SIRS SPMS UN Monoamine Oxidase B Medical Subject Headings Managing Epilepsy Well International Classification of Dis

  • Dementia
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.

THE TOLERABILITY OF ORAL EXELON ##MG/ DAY WAS SIMILAR TO THAT OF THE ##CM PATCH DELIVERING ##. ##MG/ ## HR, WITH DISCONTINUATION RATES DUE TO GASTROINTESTINAL (GI)-RELATED ADVERSE EVENTS, SUCH AS NAUSEA AND VOMITING, AT ##. ##% AND ##. ##%, RESPECTIVELY.

  • Dementia
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group

Alzheimer's disease

4546 5000 3864
  • WHILE CURRENT PHARMACOTHERAPIES ARE CONSIDERED TOLERABLE, THERE IS ALWAYS ROOM FOR IMPROVEMENT
  • Product profile (late stage): encenicline

Transdermal administration reduces the incidence of gastrointestinal side effects, such as nausea and vomiting, by two-thirds (Wentrup et al., 2008).

  • Dementia
  • Asia
  • Europe
  • Japan
  • World
  • PLANT EXTRACTS AND COMPOUNDS HAVE BEEN EXTENSIVELY REVIEWED

SUCH CHEMICALS ARE NO DOUBT BIOSYNTHESIZED TO DETER PREDATORS, AND IF INGESTED CAUSE SEVERE GASTROINTESTINAL EFFECTS.

  • Dementia
  • United States
  • World
  • Cowen & Co., LLC
  • Pfizer Inc.
  • D-Pharm Ltd. - Pipeline by Indication, 2015

This report is a licensed product and is not to be photocopied D-Pharm Ltd. has promising clinical drug candidates for ## major therapeutic areas, Central Nervous System and Gastrointestinal.

  • Dementia
  • Stroke
  • World
  • Product Initiative
  • D-Pharm Ltd.
  • Amyotrophic Lateral Sclerosis
  • MASITINIB - DRUG PROFILE

The poster presentations were entitled as " Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group Phase II trial"; " Masitinib in comparison to imatinib as first line therapy of patients with advanced

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Dementia
  • Therapy
  • United States
  • Company
  • Heptares Therapeutics Limited
  • data indicated that tyrosine kinase inhibitors are very promising candidates for new therapeutic interventions in neurological diseases.
  • MASITINIB - DRUG PROFILE

One patient had a Sprycel-related AE leading to discontinuation, and one patient died from gastrointestinal bleeding unrelated to treatment.

  • Cancer
  • Dementia
  • United States
  • Product Initiative
  • AB Science SA

Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology and Infectious Disease which include indications Alzheimer' s Disease, Liver Fibrosis, Autoimmune Disorders, Breast Cancer, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Feve

  • Dementia
  • United States
  • World
  • Product Initiative
  • Virobay Inc.
  • Therapeutics Development
  • PFIZER INC.

The drug-related AEs were elevated liver enzymes and gastrointestinal AEs.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • the functional impairment of patients assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS).
  • Other Developmental Activities

No grade ## gastrointestinal adverse events were reported.

  • Dementia
  • Hospital
  • In Vitro Diagnostic Reagent
  • Lung Cancer
  • AB Science SA

Hanmi Pharma' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Dementia
  • Pharmaceutical
  • Therapy
  • United States
  • Janssen Biotech, Inc.
  • Dementia
  • Pharmaceutical
  • United Kingdom
  • Company
  • IXICO plc

In clinical trials, the most common adverse events associated with dimethyl fumarate were flushing and gastrointestinal (GI) events.

  • Dementia
  • Pharmaceutical
  • Therapy
  • United States
  • Biogen Idec Inc.
  • 4.9 Indications Associated with Alzheimer's Disease
  • Alzheimer's Disease and Associated Indications, Global, Key Features of Presenilin 1, 2017

These drugs have also been shown to elicit a number of side effects including alterations of immune cells, gastrointestinal symptoms, skin reactions, and skin cancers.

  • Dementia
  • Mental Health
  • World
  • Deals & Alliance
  • Eli Lilly & Co.
  • Aug 31, 2017: Probiodrug reports financial results for H1 2017 and corporate update

Skin and gastrointestinal organ system related adverse events were observed in a higher frequency in the PQ## arm compared to placebo and occurred in the majority in the first half of the treatment period.

  • Dementia
  • Healthcare
  • Austria
  • United States
  • Probiodrug AG

(NYSE: GI), which offers physicians a broad portfolio of products to treat gastrointestinal conditions, for approximately $## million.

  • Clinical Trial
  • Dementia
  • Pathology
  • Therapy
  • GlobalData's company
  • Neurodegenerative Disease, Global, First-in-Class Pipeline Products With and Without Prior Involvement in Licensing or Co-

These drugs also show a harmful side-effect profile, including issues related to alterations of immune cells, gastrointestinal symptoms and skin cancers.

  • Dementia
  • Psychotic Disorder
  • World
  • Deals & Alliance
  • Biogen Idec Inc.

In this study, all doses of TTP## were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects.

  • Dementia
  • Pharmaceutical
  • United States
  • Company Operations
  • vTv Therapeutics LLC
  • Research and Development Brief
  • DEMENTIA - PIPELINE BY DAEWOONG PHARMACEUTICAL CO LTD, H1 2017

The company' s products include antiasthmatics, antidepressants, anxiolytics and hypnotics, nootropics, gastrointestinal drugs, and others.

  • Dementia
  • United States
  • World
  • Product Initiative
  • Eisai Co., Ltd.